
|Videos|June 20, 2011
Dr. Kris Discusses the Imatinib GIST Clinical Trial
Author(s)Mark G. Kris, MD, FASCO
Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial
Advertisement
Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center Discusses the Imatinib (Gleevec) gastrointestinal stromal tumors (GIST) Clinical Trial.
Dr. Kris says in a GIST clinical trial, researchers compared one year of adjuvant post-surgery imatinib to three years of adjuvant post-surgery imatinib and found a significant improvement in cancer free survival and in overall survival. By taking a medicine for two more years (four pills a day), patients stayed free of cancer and lived longer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































